Streptococcus pneumoniae polysaccharide conjugated to tetanus toxoid
Highest phase reached
Approved
Drug type
Vaccine component
First approval year
2009
- First approval year
- 2009
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Vaccine component
- Drug name
- Streptococcus pneumoniae polysaccharide conjugated to tetanus toxoid
- streptococcus pneumoniae polysaccharide conjugated to tetanus toxoid component of synflorix
- Streptococcus pneumoniae polysaccharide conjugated to tetanus toxoid component of synflorix
- streptococcus pneumoniae polysaccharide conjugated to tetanus toxoid
- Streptococcus pneumoniae polysaccharide conjugated to tetanus toxoid
- ChEMBL ID
- CHEMBL6068366
- First in class
- No
- Orphan designation
- No
Mechanisms of action
- Mechanism
- Polysaccharide conjugated to Tetanus toxoid vaccine antigen
- Action type
- VACCINE_ANTIGEN
- Target
- Polysaccharide conjugated to Tetanus toxoid
- Condition
- Pneumococcal Infections
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000772
- Subject identifier
- D011008
- Condition
- Vaccination
- Highest recorded phase
- 4
- Condition identifier
- EFO:0004292
- Subject identifier
- D014611
- Condition identifier
- EFO_1001476
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005114
- Highest recorded phase
- 4
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
Related records
Trials (63)
- A Phase 3 Study to Evaluate the Immunogenicity and Safety of Walvax's PCV13-TT as Compared to Pfizer's PCV13
- A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age
- A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age
- A Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Healthy Children 3 Months After a First Dose at 12 to 15 Months of Age
- A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of Age
- A Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK)'s Infanrix Hexa Vaccine (DTPa-HBV-IPV/Hib) Versus MCM Vaccine BV's Vaxelis Vaccine (DTaP5-HBV-IPV-Hib) in Healthy Infants and Toddlers
- A Study to Learn About a Type of Pneumococcal Vaccine With a New Ingredient (PF-07872411) Intended to Enhance the Effects of the Vaccine Which is Given to Adults
- A Study to Learn About How a New Pneumococcal Vaccine Works in Infants
- A Study to Learn How Effective is PCV20 to Help Stop Adults Who Have a Higher Chance of Getting Pneumonia
- A Study to Learn More About Prevenar 20 Once it is Out in the Korean Market
- An Alternative Booster Vaccine Against Meningitis and Ear Infections
- Assess Reacto- and Immunogenicity of Pneumococcal Conjugate Vaccine When Given as Booster or a 2 Dose Catch up Schedule
- Assessment of Novel Pneumococcal Conjugate Vaccination Scheduled in UK Infants
- Clinical Trial of the 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/Tetanus Toxoid)
- Dose-Finding Study of S.Pneumoniae Whole Cell Vaccine Adsorbed to Alum (PATH-wSP) in Healthy Kenyan Adults and Toddlers
- Immunity to Serotype 19A Streptococcus Pneumoniae in Children Vaccinated With PCV10
- Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine in Infants and Toddlers When Administered Concomitantly With Routine Pediatric Vaccines in the United Kingdom
- Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US
- Immunogenicity and Safety of a Tetanus-diphtheria Vaccine and a 13-valent Pneumococcal Conjugate Vaccine
- Immunogenicity and Safety of GlaxoSmithKline Biologicals' Infanrix™-IPV+Hib Vaccine
Approved for (1)
In development for (1)
- Streptococcal infection Phase 3